A patient in a long-term-care facility is taking Risperdal (risperidone) for a mood disorder, which is not appropriate per CMS (Centers for Medicare & Medicaid Services) guidelines; what medication recommendations would you suggest?

Discontinue Risperdal and Transition to Mood Stabilizers or Antidepressants

For a patient in long-term care taking Risperdal (risperidone) for a mood disorder, you should discontinue the antipsychotic and transition to appropriate mood disorder treatment—specifically mood stabilizers (lithium or valproate) for bipolar disorder, or SSRIs for unipolar depression. Antipsychotics like risperidone are not appropriate first-line agents for mood disorders in long-term care settings per CMS guidelines, which target reduction of inappropriate antipsychotic use in this population 1.

Understanding the Clinical Context

The key issue here is that risperidone is FDA-approved for bipolar mania and schizophrenia, not for general "mood disorders" 2. If this patient has:

• Bipolar disorder: Mood stabilizers (lithium, valproate, or carbamazepine) should be the primary treatment 3
• Unipolar depression: SSRIs are first-line therapy 4
• Behavioral symptoms of dementia: This would be the primary target of CMS antipsychotic reduction initiatives 1

Specific Transition Strategy

Step 1: Clarify the Diagnosis

Document the specific mood disorder diagnosis. CMS guidelines specifically target inappropriate antipsychotic use, particularly in dementia-related behavioral symptoms where antipsychotics carry significant mortality risk 1.

Step 2: Initiate Appropriate Mood Disorder Treatment

For Bipolar Disorder:

• Start lithium (if monitoring capabilities exist) or valproate as first-line mood stabilizer 3
• Maintenance treatment should continue for at least 2 years after the last bipolar episode 3
• Haloperidol may be used acutely for severe mania, but second-generation antipsychotics should not be routine long-term therapy 3

For Unipolar Depression:

• Initiate an SSRI (fluoxetine, sertraline, citalopram, or escitalopram) based on side effect profile, cost, and patient factors 4
• Continue treatment for 4-9 months after satisfactory response for first episode; longer for recurrent depression 4
• In nursing home residents specifically, SSRIs are recommended as first-line over tricyclics 5

Step 3: Taper Risperidone Gradually

Do not abruptly discontinue risperidone. While the evidence doesn't provide specific tapering schedules for mood disorders, gradual discontinuation over 2-4 weeks is prudent to avoid withdrawal symptoms and rebound agitation 2. Monitor closely for symptom recurrence during this period.

Step 4: Address CMS Documentation Requirements

Document clearly why antipsychotic discontinuation is occurring and what alternative treatment is being implemented 6. CMS interpretive guidelines require documentation of clinical rationale when antipsychotics are continued beyond initial stabilization 6. In this case, you're correcting inappropriate use by transitioning to evidence-based mood disorder treatment.

Critical Considerations

The CMS Antipsychotic Reduction Initiative

Since 2012, CMS has aggressively targeted antipsychotic reduction in nursing facilities, primarily focused on dementia patients but affecting all residents 1. Research shows this initiative led to significant antipsychotic reductions even in populations where they may be indicated (bipolar disorder, psychosis) 1. Your patient may have been inappropriately started on risperidone due to diagnostic confusion or convenience rather than evidence-based indication.

Risperidone's Limited Role in Mood Disorders

While risperidone has FDA approval for acute bipolar mania 2, evidence shows:

• Benefit is primarily in the first 24 weeks for mania prevention 7
• No evidence for use in unipolar depression as monotherapy 8
• Higher doses and longer duration increase adverse effects without additional benefit 9, 10

Safety Concerns in Long-Term Care

In elderly nursing home residents, risperidone carries risks of:

• Falls (6.9% incidence even at low doses) 11
• Extrapyramidal symptoms at doses >2mg/day 9, 2
• Metabolic effects with prolonged use 10
• Increased mortality risk in dementia patients (though this patient has a mood disorder, age-related vulnerability remains)

Monitoring the Transition

Assess response at 1-2 weeks initially, then at 6-8 weeks 4:

• Use standardized depression scales (Cornell Scale for Depression in Dementia if cognitive impairment present, or Geriatric Depression Scale) 5
• Monitor for mood episode recurrence
• Document target symptoms and their response to new treatment

For antidepressants specifically: If inadequate response by 6-8 weeks, modify treatment (increase dose, switch agents, or add augmentation) 4.

Common Pitfalls to Avoid

1. Don't substitute with another antipsychotic unless there's documented psychosis or treatment-resistant bipolar disorder requiring adjunctive therapy
2. Don't use benzodiazepines as a replacement strategy—CMS also scrutinizes these, and they increase fall risk 11
3. Don't attempt dose reduction of risperidone while keeping it long-term—this doesn't address the fundamental issue of inappropriate medication class 6
4. Don't assume "mood disorder" justifies antipsychotic use—mood stabilizers and antidepressants are the evidence-based treatments 3, 4

The bottom line: Risperidone should be discontinued and replaced with appropriate mood disorder pharmacotherapy (mood stabilizers for bipolar disorder, SSRIs for depression) with gradual taper and close monitoring during transition.